{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bae S"],"funding":["National Institute of Allergy and Infectious Diseases","National Institute of Diabetes and Digestive and Kidney Diseases","NIDDK NIH HHS","NIA NIH HHS","NIAID NIH HHS","National Institute on Aging"],"pagination":["662-670"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11960740"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["40(4)"],"pubmed_abstract":["Background
Early steroid withdrawal (ESW) is often preferred over conventional steroid maintenance (CSM) therapy for kidney transplant recipients with low immunological risks because it may minimize immunosuppression-related adverse events while achieving similar transplant outcomes. However, the risk-benefit balance of ESW could be less favorable in retransplant recipients given their unique immunological risk profile. We hypothesized that the association of ESW with transplant outcomes would differ between first-transplant and retransplant recipients.Methods
To assess whether the impact of ESW differs between first and retransplant recipients, we studied 210 086 adult deceased-donor kidney transplant recipients using the Scientific Registry of Transplant Recipients. Recip"],"journal":["Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association"],"pubmed_title":["Early steroid withdrawal and kidney transplant outcomes in first-transplant and retransplant recipients."],"pmcid":["PMC11960740"],"funding_grant_id":["R01DK120518","K02AG076883","K01 DK132490","K24 AI144954","K24AI144954","K01DK132490","R01 DK120518","K02 AG076883"],"pubmed_authors":["Sandal S","McAdams DeMarco MA","Bae S","Chen Y","Lentine KL","Schnitzler M","Segev DL"],"additional_accession":[]},"is_claimable":false,"name":"Early steroid withdrawal and kidney transplant outcomes in first-transplant and retransplant recipients.","description":"Background
Early steroid withdrawal (ESW) is often preferred over conventional steroid maintenance (CSM) therapy for kidney transplant recipients with low immunological risks because it may minimize immunosuppression-related adverse events while achieving similar transplant outcomes. However, the risk-benefit balance of ESW could be less favorable in retransplant recipients given their unique immunological risk profile. We hypothesized that the association of ESW with transplant outcomes would differ between first-transplant and retransplant recipients.Methods
To assess whether the impact of ESW differs between first and retransplant recipients, we studied 210 086 adult deceased-donor kidney transplant recipients using the Scientific Registry of Transplant Recipients. Recip","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-03T21:37:00.963Z","creation":"2026-05-02T03:07:57.008Z"},"accession":"S-EPMC11960740","cross_references":{"pubmed":["39349991"],"doi":["10.1093/ndt/gfae218"]}}